相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle
Barbara M. Parker et al.
PHARMACOGENOMICS (2018)
Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Anastasios Lymperopoulos et al.
CURRENT DRUG METABOLISM (2016)
Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach
Muhammad Fawad Rasool et al.
DRUG METABOLISM AND DISPOSITION (2016)
Dealing with the complex drug-drug interactions: Towards mechanistic models
Manthena V. Varma et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2015)
Clinical implications from drug-drug and drug-disease interactions in older people
Danijela Gnjidic et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2013)
Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine
Akiko Mikami et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
The P-Glycoprotein Transport System and Cardiovascular Drugs
Jeffrey D. Wessler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Mutual Inhibition between Carvedilol Enantiomers during Racemate Glucuronidation Mediated by Human Liver and Intestinal Microsomes
Yoh Takekuma et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2012)
Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetine
Stephen M. Stout et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics
Daniel Sehrt et al.
PHARMACOGENOMICS (2011)
Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling Two Cytochrome P450 3A4 Substrates Coadministered with Ketoconazole or Verapamil
Nathalie Perdaems et al.
CLINICAL PHARMACOKINETICS (2010)
The Impact of Paroxetine Coadministration on Stereospecific Carvedilol Pharmacokinetics
Stephen M. Stout et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
Population-Based Mechanistic Prediction of Oral Drug Absorption
Masoud Jamei et al.
AAPS JOURNAL (2009)
Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers
T Aiba et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects
T Giessmann et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol
A Ohno et al.
DRUG METABOLISM AND DISPOSITION (2004)
Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination
LM Berezhkovskiy
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Metabolic drug interactions with new psychotropic agents
E Spina et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2003)
Inhibition of P-glycoprotein by newer antidepressants
J Weiss et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients
DW Graff et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure
D Tenero et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
